

Iranian Journal of Blood & Cancer

Journal Home Page: www.ijbc.ir



ORIGINAL ARTICLE

Association between Cytochrome P450 2C19 Gene Polymorphisms and Hematological Malignancies in an Iranian Population

Mehdi Mohammadi¹, Molouk Hadjibabaie^{2,3}, Elham Khalili⁴, Sholeh Ebrahimpour^{5*}

¹Department of Clinical Pharmacy, School of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran ²Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran ³Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran ⁴Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran ⁵Department of Clinical Pharmacy, Virtual University of Medical Sciences, Tehran, Iran

ABSTRACT

ARTICLE INFO

Article History: Received: 03.02.2019 Accepted: 11.05.2019

Keywords:

CYP2C19

the contribution of the CYP2C19 polymorphisms to different malignancies. We aimed to investigate the association between CYP2C19 polymorphism and occurrence of hematological malignancies by comparing the phenotype distribution of this enzyme in patients and healthy subjects. Gene polymorphism Methods: 150 Iranian patients with hematological malignancies from different Hematological malignancies ethnicities were recruited. Mutant alleles of the CYP2C19*2 and *3 were examined using PCR-RFLP technique and CYP2C19*17 was genotyped using DNA sequencing analysis. Results: CYP2C19*17 was the most common allelic variation (24%, 95% CI: 19.17-28.83%) among patients with hematological malignancies, whereas the variant CYP2C19*3 was not detected among our patients. Furthermore, the CYP2C19*1*1 and CYP2C19*1*17 genotypes which respectively represented the "extensive metabolizer" (EM) and Ultra-rapid metabolizer (URM) phenotypes, *Corresponding author: had the highest incidence. Sholeh Ebrahimpour No. 3, 1st St., Sarafraz St., Shahid Conclusion: The results of this study suggested that there may be no association Beheshti St., Tehran, Iran. between CYP2C19 polymorphisms and occurrence of hematological

Background: Cytochrome P450 2C19 (CYP2C19) is widely involved in the

metabolism of some medications. On the other hand, recent studies have shown

malignancies. However, larger well-designed studies are necessary to confirm Fax: +98-21-66438632. these results in Iranian populations. Email: hawar_327ph@yahoo.com

Please cite this article as: Mohammadi M, Hadjibabaie M, Khalili E, Ebrahimpour S. Association between Cytochrome P450 2C19 Gene Polymorphisms and Hematological Malignancies in an Iranian Population. IJBC 2019; 11(3): 85-90.

Introduction

Tel: +98-21-66125610

Several factors have been identified to date that have a role in the development of cancers. They include, but are not limited to environmental carcinogens and lifestyle variables. However, these factors do not affect the entire population similarly. Therefore, substantial inter-individual variability in cancer development is observed with similar exposure profiles. Beside various factors which contribute to individual susceptibility to cancer development, the role of genetic polymorphism of hepatic enzymes has also been proposed. The superfamily of cytochrome P450 enzymes is responsible

for the metabolism of xenobiotics such as drugs and toxic chemicals. The carcinogenic effects of xenobiotics may either increase or decrease under the influence of cytochrome enzymes. Polymorphisms in genes encoding the liver enzymes are associated with altered enzyme function and subsequent alteration in the carcinogenecity of toxic chemicals. In order to clarify their role in cancer development, various isoenzymes of this superfamily have been explored including CYP2C19 and CYP2D6 and their impact to some types of cancers have been revealed.¹

CYP2C19, known as the second major CYP enzyme is widely involved in the metabolism of various medications.^{2,3} Based on published studies to date, more than 35 allele variants have been identified for CYP2C19.⁴ The extent of drug and xenobiotic metabolism could be affected dramatically by these allelic variants. Compared to CYP2C19*1, as the wild type allele with normal enzymatic function, the CYP2C19*2 and CYP2C19*3 are known as defective alleles associated with poor metabolism. On the contrary, the novel variant of CYP2C19*17 is characterized by enhanced enzymatic function resulting from increased enzyme transcription.^{5,6}

Previous studies have indicated significant differences in the distribution of CYP2C19*17 allele among Polish and Korean population which were 28.2% and 0.3%, respectively.^{7,8} Other studies demonstrated remarkable differences in the distribution of CYP2C19*2 and CYP2C19*3 alleles in Korean and Turkish populations which were 28.4% *vs.* 10% for CYP2C19*2 and 10.1% *vs.* 0.0% for CYP2C19*3, respectively.^{9,10}

There is growing evidence that reveals the association between CYP2C19 polymorphism and occurrence of different types of cancer including those of esophagus, colorectum, stomach, biliary tract, and lung. This could be explained by the major role of CYP2C19 in detoxification of carcinogens and bioactivation of procarcinogenic compounds.^{11,12}

We aimed to investigate the distribution of the CYP2C19 polymorphisms in Iranian patients with hematological malignancies and explore its association with the occurrence of underlying cancer.

Materials and Methods

Patient Description and Ethical Statement

One hundred and fifty Iranian patients with hematological malignancies referring to the Shariati Hospital, Tehran University of Medical Sciences, between October 2015 and September 2016 were enrolled in the study. The mean age of participants was 37.0 ± 15.3 years, ranging from 16 to 82 years. Written consent for the molecular study, genetic research, and publishing results was obtained from the patients. Furthermore, the Ethics Committee of Tehran University of Medical Sciences specifically approved this prospective cross-sectional study. Healthy individuals were chosen as the control group from a previously published study on the Iranian population.¹³

Genomic DNA Extraction

Genomic DNA was extracted from 5 mL of EDTAtreated whole blood samples using blood DNA kit (QIAamp® DNA Micro Kit #56304, QIAGEN, Hilden, Germany) according to the manufacturer's instruction. Purity and concentration of the extracted DNA were evaluated using Nanodrop 1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE).

Polymerase Chain Reaction (PCR) and Primer Designs

PCR was done in a final volume of 25 μ L containing 100-200 ng of genomic DNA, 10 pmol of each primer (Table 1), 2.5 mM MgCl2, 200 mM of each dNTP, and 1 U of superTaq DNA polymerase (Roche Diagnostics, Mannheim, Germany). Thermocycling schedule for DNA amplification was planned as an initial denaturation at 94 °C for 5 min, followed by 30 cycles of denaturation at 94 °C for 1 min, annealing at 58 °C for 1 min, and elongation at 72 °C for 50 sec with a final incubation for 10 min at 72 °C. The oligonucleotide forward and reverse primers that were used to amplify CYP2C19 SNP were ordered as described previously.¹⁴

Restriction Fragment Length Polymorphism (RFLP)

The PCR products were digested with *SmaI* and *BamHI* (Fermentas, Thermo Scientific) for CYP2C19*2 (rs4244258) and CYP2C19*3 (rs4986893), respectively. Digested PCR products were analyzed using electrophoresis on a 3% agarose gel (Bio-Rad). The *SmaI* digested the 223 bp fragment to 110 bp and 113 bp fragments in wild type carrying CYP2C19*1. Digestion by *BamHI* led to the production of 142 bp and 114 bp fragments in wild type carrying CYP2C19*1. Separation of a single band through gel electrophoresis represents homozygous genotype of CYP2C19*2 and *3 (Table 1; Figure 1).

DNA Sequencing Analysis

Genotyping of the CYP2C19*17 allele was performed using DNA sequencing analysis (Figure 2), but genotyping of the CYP2C19*2 and CYP2C19*3 alleles were carried out using polymerase chain reaction RFLP (PCR-RFLP). The PCR products were sequenced using an ABI 3700 sequencer machine (Kosar Company, Tehran, Iran). All

Table 1: Details of the associated primer sequences, PCR product size, restriction endonucleases, and digested fragments of PCR products

CYP2C19 SNP	Primer sequence (14)	PCR product size (bp)	Restriction endonuclease, Temperature (°C)	Restriction pattern (bp)	Accession
CYP2C19*2	CAACCAGAGCTTGGCATATTG (F)	223	SmaI (30)	Wt: 113-110	NM_000769.2:c.
rs4244258	TAAAGTCCCGAGGGTTGTTG (R)			Mt: 223	681G>A
				Het: 223-110-113	
CYP2C19*3	CTGCAATGTGATCTGCTCCA (F)	256	BamHI (37)	Wt: 142-114	NM_000769.2:c.
rs4986893	ATTCACCCCATGGCTGTCTA (R)			Mt: 256	636G>A
				Het: 142 -114-256	
CYP2C19*17	GCCTGTTTTATGAACAGGATGA (F)	215	-	-	NM_000769.2:c.
rs12248560	CACAGCTCATAGCTGGCAGA (R)				806C>T
SNP: Single 1	Nucleotide Polymorphism; bp: base pair	F: Forward	primer: R: Reverse	e primer; Wt: Wild	type; Mt: Muta

SNP: Single Nucleotide Polymorphism; bp: base pair; F: Forward primer; R: Reverse primer; Wt: Wild type; Mt: Mutant (homozygous); Het: Heterozygous mutant




Figure 1: Sequence chromatogram of CYP2C19*17 (-806C>T) SNP




Figure 2: CYP2C19*2 Lane 1: Het mutant (223 bp, 113 bp, 110 bp), Lane 2: Mutant (223 bp), Lane 3: Wt (113 bp, 110 bp), Lane 4: PCR product (223 bp); CYP2C19*3 Lane 5: Wt (142 bp, 114 bp), Lane 6: PCR product (256 bp), Lane 7: ladder (100 bp)

fragments were then compared with controls using the FinchTV software (http://www.geospiza.com/finchtv/) and the NCBI website (available online at: http://blast. ncbi.nlm.nih.gov/Blast.cgi) for confirmation of any nucleotide variation.

Statistics

The statistical analyses were conducted using SPSS 17.0 to perform the chi-square and two-tailed Fisher's exact tests for comparison of the genotype and allele frequencies between patients with hematological malignancies and unrelated healthy individuals in an Iranian population of different ethnicities.

Confidence intervals were stated at the 95% confidence level for genotype and allele frequencies. A P value of less than 0.05 (P<0.05) was considered statistically significant.

Results

Downloaded from ijbc.ir on 2024-05-01

One hundred and fifty patients with hematological malignancy including 87 men and 63 women were recruited in this study. The underlying hematological malignancies consisted of AML (n:113), ALL (n:23), CML (n:6), NHL (n:4), CLL (n:2), HD (n:1), and one patient with multiple myeloma. The participants were examined to identify the allelic and genotypic distribution of CYP2C19. The CYP2C19*17 was the most common allelic variation (24.0%; 95% CI: 19.17-28.83%), whereas CYP2C19*3 was not detected among

patients. CYP2C19*1*1 genotype, representing the Extensive Metabolizer (EM) phenotype, indicated the highest incidence. CYP2C19*1*17 and CYP2C19*17*17 which are associated with Ultra-rapid Metabolizer (URM) phenotype were detected in 37.3% of patients. Genotypes corresponding for Intermediate Metabolizer (IM) phenotype, which includes CYP2C19*2*17 and CYP2C19*1*2 were observed in 27.3% of the patients. The Poor Metabolizer (PM) phenotype, carrying the CYP2C19*2*2 genotype was identified in only one patient. The allelic and genotypic frequencies are summarized in Table 2.

Results of our study were compared with those previously reported for healthy individuals in Iranian population.¹³ There were no significant differences in the distribution of CYP2C19*1 (61.7% vs. 65.3%; P=0.39), CYP2C19*2 (14.3% vs. 13.0%; P=0.56), CYP2C19*3 (0.0% vs. 0.0%; P=0.99), and CYP2C19*17 (24.0% vs. 21.7%; P=0.48) alleles between the two groups of patients with hematologic malignancy and normal control. Additionally, there were no significant differences in the distribution of CYP2C19*17*17 (6.0% vs. 5.5%; P=0.76), CYP2C19*1*17 (31.3% vs. 28.9%; P=0.62), CYP2C19*1*1 (34.7% vs. 41.7%; P=0.19), CYP2C19*2*17 (4.7% vs. 3.3%; P=0.53), CYP2C19*1*2 (22.7% vs. 18.3%; P=0.33), and CYP2C19*2*2 (0.7% vs. 2.2%; P=0.24) genotypes between the patients and healthy population.

 Table 2: Genotype and allele frequency of CYP2C19 among Iranian patients with hematologic malignancies (n=150). Genotype combinations were used to categorize CYP2C19 phenotypes as PM, IM, and EM

CYP2C19 Genotype	Nu	mber of subjects	Frequency; % (95% CI)	Predicted phenotype		
	Men	Women				
1*1	28	24	34.67 (27.05-42.29)	EM		
1*17	28	19	31.33 (23.9-38.75)	URM		
1*2	22	12	22.67 (15.96-29.37)	IM		
2*17	2	5	4.67 (1.29-8.04)	IM		
17*17	6	3	6.00 (2.20-9.80)	URM		
2*2	1	0	0.67 (0.63-1.97)	PM		
3*3	0	0	0.00	PM		
Alleles	Number of alleles		Frequency; % (95% CI)	,		
CYP2C19*1	185		61.67 (56.17-67.17)			
CYP2C19*17	72		24.0 (19.17-28.83)			
CYP2C19*2	43		14.33 (10.36-18.29)			
CYP2C19*3	0		0			

CI: Confidence Interval; EM: Extensive Metabolizer; IM: Intermediate Metabolizer; URM: Ultra-Rapid Metabolizer; PM: Poor Metabolizer

Discussion

To the best of our knowledge, this is the first study revealing the allelic and genotypic frequencies of CYP2C19*2,*3 and *17 among Iranian patients with hematological malignancies. The allelic frequencies of CYP2C19*1, *2, *3, and *17 in our study were in parallel with the previous study on healthy Iranian adults. Well-matched results were also observed for genotype frequencies.¹³ Iran is a multi-ethnic country with different ethnic groups and this diversity was reflected in our patients who were recruited from ten different ethnicities. Payan and colleagues13 included participants from only four cities which could not properly reflect the multi-ethnic nature of the Iranian population. Therefore, we further compared our findings with the results of two other studies conducted on healthy individuals from Baluch and Mazani Iranian ethnicities (Table 3).^{15,16} In another study allelic and genotypic frequencies of CYP2C19*1, *2, and *3 were examined on healthy participants of Baluch ethnicity.15 Frequency of CYP2C19*2 and *3 were in line with previous

results reported by Payan et al., whereas frequencies for CYP2C19*1 allele and CYP2C19*1*1 genotype were significantly different from their findings (P=0.001) (Table 3). It should be noted that the allele frequency of CYP2C19*17 was not investigated in Ghiyas Tabari et al.¹⁵ study, therefore this allele was identified as CYP2C19*1. If the frequency of CYP2C19*17 (21.7%) reported by Payan et al. be subtracted from CYP2C19*1 frequency (88.9%) in Ghiyas Tabari's study, the resulting values for CYP2C19*1 frequency will be close to each other (67.2% vs. 61.3%). Similar frequencies for CYP2C19*1*1 genotype would also be obtained accordingly. Since CYP2C19*1*17 and CYP2C19*17*17 allels were recognized as CYP2C19*1*1 in Ghiyas Tabari's study, the actual frequency of CYP2C19*1*1 would be obtained by subtracting the frequencies of CYP2C19*1*17 (28.9%) and CYP2C19*17*17 (5.5%) genotypes of Payan et al. study from CYP2C19*1*1 (78.6%) frequency reported by Ghiyas Tabari et al. study (44.2% vs. 41.2%). Since CYP2C19*17 was not investigated in Mazani population, the difference in CYP2C19*1 and CYP2C19*1*1

Table 5: Comparison of CTP2CT9 anele and genotype frequencies between current and previous published studies											
Study	Population Sample CYP2C19 allele frequent		CYP2C19 allele frequency	CYP2C19 genotype frequency (%) (significant P values)							
	(Setting)	size	(%) (significant P values)								

ropulation	size			CTTECTS genotype frequency (70) (significant f values)											
(Setting)		(%) (significant P values)													
		*1	*2	*3	*17	17*17	1*17	1*1	2*17	3*17	1*2	1*3	2*2	3*3	2*3
Hemato- logical ma- lignancy	150	61.67	14.33	0	24	6	31.33	34.67	4.67	0	22.67	0	0.67	0	0
Baluch (unrelated healthy)	140	88.93 (P =0.001)	10	1.07 (P =0.04)	NR	NR	NR	78.57 (P =0.001)	NR	NR	20.0	0.71	0	0.71	0
Mazani (unrelated healthy)_	103	91 (P =0.001)	9	0	NR	NR	NR	84 (P =0.001)	NR	NR	14	0	2	0	0
Four cities (unrelated healthy)	180	65.3	13	0	21.7	5.5	28.9	41.7	3.3)	0	18.3	0	2.2	0	0
	(Setting) Hemato- logical ma- lignancy Baluch (unrelated healthy) Mazani (unrelated healthy)_ Four cities (unrelated	(Setting)sizeHemato- logical ma- lignancy150 logical ma- lignancyBaluch (unrelated healthy)140 (unrelated healthy)Mazani (unrelated healthy)103 logical logical logical logical logical logical margingFour cities (unrelated healthy)180 logical logical	(Setting)size $(%)$ (si *1Hemato- logical ma- lignancy15061.67Baluch14088.93(unrelated healthy)(PMazani10391(unrelated healthy)_(PFour cities18065.3(unrelated65.3	(Setting)size(%) (significal $*1$ Hemato- logical ma- lignancy150 61.67 14.33 Baluch (unrelated healthy)140 88.93 10 (PMazani (unrelated healthy)103 91 9 (PMazani 	(Setting) size (%) (significant P value) $*1$ $*2$ $*3$ Hemato- logical ma- lignancy 150 61.67 14.33 0 Baluch 140 88.93 10 1.07 (unrelated healthy) 103 91 9 0 Mazani 103 91 9 0 (unrelated healthy) $=0.001$) $=0.001$ $=0.001$ Four cities 180 65.3 13 0	(Setting) size (%) (significant P values) $*1$ $*2$ $*3$ $*17$ Hemato- logical ma- lignancy 150 61.67 14.33 0 24 Baluch (unrelated healthy) 140 88.93 10 1.07 NR (unrelated healthy) 103 91 9 0 NR (unrelated healthy) 103 91 9 0 NR Four cities 180 65.3 13 0 21.7	(Setting) size (%) (significant P values) $*1$ $*2$ $*3$ $*17$ $17*17$ Hemato- logical ma- lignancy 150 61.67 14.33 0 24 6 Baluch (unrelated healthy) 140 88.93 10 1.07 NR NR Mazani (unrelated healthy) 103 91 9 0 NR NR Four cities (unrelated 180 65.3 13 0 21.7 5.5	(Setting) size (%) (significant P values) $*1$ $*2$ $*3$ $*17$ $17*17$ $1*17$ Hemato- logical ma- lignancy 150 61.67 14.33 0 24 6 31.33 Baluch (unrelated healthy) 140 88.93 10 1.07 NR NR NR Mazani (unrelated healthy) 103 91 9 0 NR NR NR Mazani (unrelated healthy) 103 91 9 0 NR NR NR Four cities (unrelated 180 65.3 13 0 21.7 5.5 28.9	(Setting) size (%) (significant P values) (%) *1 *2 *3 *17 17*17 1*17 1*1 Hemato- logical ma- lignancy 150 61.67 14.33 0 24 6 31.33 34.67 Baluch healthy) 140 88.93 10 1.07 NR NR NR 78.57 (unrelated healthy) 103 91 9 0 NR NR NR 84 (unrelated healthy) 103 91 9 0 NR NR 84 (unrelated healthy) 65.3 13 0 21.7 5.5 28.9 41.7	(Setting) size (%) (significant P values) 1 2 1 $*2$ $*3$ $*17$ 1717 $1*17$ $1*1$ $2*17$ Hemato- logical ma- lignancy 150 61.67 14.33 0 24 6 31.33 34.67 4.67 Baluch (unrelated healthy) 140 88.93 10 1.07 NR NR NR 78.57 NR Mazani (unrelated healthy) 103 91 9 0 NR NR NR 84 NR Four cities 180 65.3 13 0 21.7 5.5 28.9 41.7 3.3)	(Setting) size (%) (significant P values) Image: Normal and the set of the set	(Setting)size(%) (significant P values) $1 \times 1 \times$	(Setting)size(%) (significant P values) $1 + 17 + 17 + 141 + 17 + 141 +$	(Setting)size(%) (significant P value) $V = V = V = V = V = V = V = V = V = V =$	(Setting)size(%) (significant P values) $1 \times 1 \times$

frequencies of Payan et al. study with this population could be justified in the same way.¹⁶ Therefore, it could be claimed that the distribution of CYP2C19 polymorphism in our study was not significantly different from those reported in previous studies.

Regardless of the ethnolinguistic diversity of the Iranian population, Farjadian and colleagues conducted a study on different Iranian ethnicities and demonstrated that all Iranian ethnicities are branched from the same origin which is in close proximity to the eastern Mediterranean region.¹⁷ Considering the similar distribution of CYP2C19 polymorphisms obtained from the aforementioned studies, and the findings of the mentioned study, it could be claimed that the main findings of our study were not confounded by ethnic diversity in the Iranian population.

In reviewing the literature, there was a significant association between CYP2C19 polymorphism and incidence of some cancers. A remarkable association between PM phenotype of CYP2C19 and risk of digestive tract cancers was demonstrated in a meta-analysis by Zhou and colleagues.¹² This association could be justified by the role of CYP2C19 in detoxification of carcinogens and activation of procarcinogenic agents.12 Sameer and colleagues conducted a study on 52 children with hematological malignancies in the Gaza strip and distribution of the CYP2C19 polymorphisms were determined and compared with 200 healthy subjects. Their findings showed that there was no significant association between CYP2C19 polymorphism and the occurrence of hematological malignancies.18 With respect to long-term exposure of adults to environmental carcinogenic and procarcinogenic compounds, such association remains a matter of debate in adults.

The allelic and genotypic distribution of CYP2C19 were similar between our study population and the control group of healthy Iranian subjects. These findings are consistent with those of Sameer et al. which found no association between CYP2C19 polymorphism and the occurrence of hematological malignancies in children.¹⁸ Although preliminary, it could be suggested that there is no association between CYP2C19 polymorphism and occurrence of hematological malignancies.

The sample size of the study was not large enough to investigate the association of CYP2C19 polymorphisms and each specific hematological malignancy.

Conclusion

The evidence from this study suggested that the distribution of CYP2C19 allelic and genotypic frequencies was not significantly different between patients with hematological malignancies and healthy individuals. Hence, we found no association between cytochrome CYP2C19 gene polymorphism and occurrence of hematological malignancies, suggesting that this polymorphism may not be a risk factor for patients with such malignancies among Iranian population of different ethnicities.

Conflict of Interest: None declared.

References

- Bhat GA, Bhat AB, Lone MM, Dar NA. Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir. Nutr Cancer. 2017;69(4):585-92. doi: 10.1080/01635581.2017.1299874. PubMed PMID: 28368717.
- Gurbel PA, Shuldiner AR, Bliden KP, Ryan K, Pakyz RE, Tantry US. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J. 2011;161(3):598-604. doi: 10.1016/j.ahj.2010.12.011. PubMed PMID: 21392617. PubMed Central PMCID: PMC3061841.
- Lamoureux F, Duflot T, Woillard JB, Metsu D, Pereira T, Compagnon P, et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents. 2016;47(2):124-31. doi: 10.1016/j. ijantimicag.2015.12.003. PubMed PMID: 26775563.
- 4. CYP2C19 allele nomenclature. http://www. cypalleles.ki.se/cyp2c19.htm. Accessed Jan 3, 2017.
- Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, et al. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol. 2010;66(12):1199-205. doi: 10.1007/s00228-010-0864-8. PubMed PMID: 20665013.
- Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-13. doi: 10.1016/j.clpt.2005.10.002. PubMed PMID: 16413245.
- Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol. 2006;62(10):877-80. doi: 10.1007/s00228-006-0183-2. PubMed PMID: 16912869.
- Ramsjo M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol. 2010;66(9):871-7. doi: 10.1007/ s00228-010-0835-0. PubMed PMID: 20499227.
- Gumus E, Karaca O, Babaoglu MO, Baysoy G, Balamtekin N, Demir H, et al. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol. 2012;68(5):629-36. doi: 10.1007/s00228-011-1151-z. PubMed PMID: 22076562.
- Kim KA, Song WK, Kim KR, Park JY. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect

the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J Clin Pharm Ther. 2010;35(6):697-703. doi: 10.1111/j.1365-2710.2009.01069.x. PubMed PMID: 21054462.

- Shi W-X, Chen S-Q. Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World Journal of Gastroenterology : WJG. 2004;10(13):1961-3. doi: 10.3748/wjg.v10. i13.463. PubMed PMID: PMC4572240.
- Zhou B, Song Z, Qian M, Li L, Gong J, Zou S. Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects. PLoS One. 2013;8(7):e66865. doi: 10.1371/journal.pone.0066865. PubMed PMID: 23874401. PubMed Central PMCID: PMC3712993.
- Payan M, Tajik N, Rouini MR, Ghahremani MH. Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population. Med J Islam Repub Iran. 2015;29:269. PubMed PMID: 26793660. PubMed Central PMCID: PMC4715407.
- Al-Jenoobi FI, Alkharfy KM, Alghamdi AM, Bagulb KM, Al-Mohizea AM, Al-Muhsen S, et al. CYP2C19 genetic polymorphism in Saudi Arabians. Basic Clin Pharmacol Toxicol. 2013;112(1):50-4. doi:

10.1111/j.1742-7843.2012.00919.x. PubMed PMID: 22747643.

- Tabari MG, Naseri F, Ataby MA, Marjani A. Genetic Polymorphism of Cytochrome p450 (2C9) Enzyme in Iranian Baluch Ethnic Group. The Open Biochemistry Journal. 2015;9:37-41. doi: 10.2174/1874091X01509010037. PubMed PMID: PMC4598382.
- Hashemi-Soteh SM, Shahabi-Majd N, Gholizadeh AR, Shiran MR. Allele and genotype frequencies of CYP2C9 within an Iranian population (Mazandaran). Genet Test Mol Biomarkers. 2012;16(7):817-21. doi: 10.1089/gtmb.2011.0301. PubMed PMID: 22288731.
- Farjadian S, Ota M, Inoko H, Ghaderi A. The genetic relationship among Iranian ethnic groups: an anthropological view based on HLA class II gene polymorphism. Mol Biol Rep. 2009;36(7):1943-50. doi: 10.1007/s11033-008-9403-4. PubMed PMID: 18979226.
- Sameer AE, Amany GM, Abdela AA, Fadel SA. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol. 2009;16(1):e156-62. PubMed PMID: 19193970.